Liqrev (Sildenafil Citrate) Patent Expiration, LOE Window & CMS Spending
Liqrev (Sildenafil Citrate) by Cmp: FDA Orange Book LOE 2038-12-24, 37 AB generics, $154K 2024 CMS Part D & Medicaid spend, and $1,895 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Cmp |
| FDA Application & Pathway | N214952 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2038-12-24 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 37 |
| 2024 CMS Total Public Spend | $154K |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $154K |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($1,895 intro WAC) |